The introduction of new-age antidiabetic drugs; such as Dipeptidyl peptidase-4 (DPP-4) inhibitors had fundamentally changed the treatment settings for type 2 diabetes mellitus (T2DM). DPP-4 inhibitors elevate endogenous glucagon-like peptide-1 concentrations, stimulating insulin secretion, and inhibiting glucagon secretion. DPP-4 inhibitors possess a favorable safety profile, do not elevate intrinsic hypoglycemia risk, and have demonstrated cardioprotective and nephroprotective benefits.
1 Many national and international guidelines, including The American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD), have incorporated DPP-4 inhibitors are positioned as second-line therapy. Moreover, they are recommended in triple therapies as well. 1,2 In this regard, Boehringer Ingelheim India and Docplexus have organized a Multi-specialty Panel discussion…
